Claims for Patent: 6,083,702

Summary for Patent: 6,083,702

Title:	Methods and compositions for use in spliceosome mediated RNA trans-splicing
Abstract:	The molecules and methods of the present invention provide a means for in vivo production of a trans-spliced molecule in a selected subset of cells. The pre-trans-splicing molecules of the invention are substrates for a trans-splicing reaction between the pre-trans-splicing molecules and a pre-mRNA which is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides a novel mRNA which is functional as mRNA or encodes a protein to be expressed in the target cells. The expression product of the mRNA is a protein of therapeutic value to the cell or host organism a toxin which causes killing of the specific cells or a novel protein not normally present in such cells. The invention further provides PTMs that have been genetically engineered for the identification of exon/intron boundaries of pre-mRNA molecules using an exon tagging method. The PTMs of the invention can also be designed to result in the production of chimeric RNA encoding for peptide affinity purification tags which can be used to purify and identify proteins expressed in a specific cell type.
Inventor(s):	Mitchell; Lloyd G. (Durham, NC), Garcia-Blanco; Mariano A. (Durham, NC)
Assignee:	Intronn Holdings LLC (Silver Spring, MD)
Application Number:	09/133,717
Patent Claims:	1. A cell comprising a nucleic acid molecule wherein said nucleic acid molecule comprises: a) one or more target binding domains wherein the target binding domain is a random nucleotide sequence that targets binding to a pre-mRNA expressed within the cell; b) a 3' splice region comprising a branch point, a pyrimidine tract and a 3' splice acceptor site; c) a spacer region that separates the 3' splice region from the target binding domain; and d) a nucleotide sequence to be trans-spliced to the target pre-mRNA; wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell. 2. A cell comprising a nucleic acid molecule wherein said nucleic acid molecule comprises: a) one or more target binding domains wherein the target binding domain is a random nucleotide sequence that targets binding to a pre-mRNA expressed within the cell; b) a 5' splice site; c) a spacer region that separates the 5' splice site from the target binding domain; and d) a nucleotide sequence to be trans-spliced to the target pre-mRNA; wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell. 3. The cell of claim 1 wherein the nucleic acid molecule further comprises a 5' donor site. 4. The cell of claim 1 wherein the nucleic acid molecule further comprises a safety nucleotide sequence comprising one or more complementary sequences that bind to one or more sides of the 3' splice region. 5. The cell of claim 1 wherein the binding of the nucleic acid molecule to the target pre-mRNA is mediated by complementarity, triple helix formation, or protein-nucleic acid interaction. 6. The cell of claim 1 wherein the nucleotide sequences to be trans-spliced to the target pre mRNA comprises sequences encoding a translatable polypeptide tag. 7. The cell of claim 1 wherein the nucleotide sequences to be trans-spliced to the target pre-mRNA comprises a nucleotide sequence tag. 8. A cell comprising a recombinant vector wherein said vector expresses a nucleic acid molecule comprising: a) one or more target binding domains wherein the target binding, domain is a random nucleotide sequence that targets binding to a pre-mRNA expressed within the cell; b) a 3' splice region comprising a branch point, a pyrimidine tract and a 3' splice acceptor site; c) a spacer region that separates the 3' splice region from the target binding domain; and d) a nucleotide sequence to be trans-spliced to the target pre-mRNA; wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell. 9. A cell comprising a recombinant vector wherein said vector expresses a nucleic acid molecule comprising: a) one or more target binding domains wherein the target binding domain is a random nucleotide sequence that targets binding to a pre-mRNA expressed within the cell; b) a 5' splice site; c) a spacer region that separates the 5' splice site from the target binding domain; and d) a nucleotide sequence to be trans-spliced to the target pre-mRNA; wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell. 10. The cell of claim 8 wherein the nucleic acid molecule further comprises a 5' donor site. 11. A method of producing a chimeric RNA molecule in a cell comprising: contacting a target pre-mRNA expressed in the cell with a nucleic acid molecule recognized by nuclear splicing components wherein said nucleic acid molecule comprises: a) one or more target binding domains wherein the target binding domain is a random nucleotide sequence that targets binding to a pre-mRNA expressed within the cell; b) a 3' splice region comprising a branch point, a pyrimidine tract and a 3' splice acceptor site; c) a spacer region that separates the 3' splice region from the target binding domain; and d) a nucleotide sequence to be trans-spliced to the target pre-mRNA; under conditions in which a portion of the nucleic acid molecule is trans-spliced to a portion of the target pre-mRNA to form a chimeric RNA within the cell. 12. A method of producing a chimeric RNA molecule in a cell comprising: contacting a target pre-mRNA expressed within the cell with a nucleic acid molecule recognized by nuclear splicing components wherein said nucleic acid molecule comprises: a) one or more target binding domains wherein the target binding domain is a random nucleotide sequence that targets binding to a pre-mRNA expressed within the cell; b) a 5' splice site; c) a spacer region that separates the 5' splice site from the target bindings domain; and (d) a nucleotide sequence to be trans-spliced to the target pre-mRNA; wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell. 13. A method of claim 11 wherein the nucleic acid molecule further comprises a 5" donor site. 14. The method of claim 11, wherein the chimeric RNA molecule comprises sequences encode a translatable polypeptide tag. 15. The method of claim 11, wherein the chimeric RNA molecule comprises a nucleotide sequence tag. 16. A nucleic acid molecule comprising: a) one or more target binding domains wherein the target binding domain is a random nucleotide sequence that targets binding to a pre-mRNA expressed within the cell; b) a 3' splice region comprising a branch point a pyrimidine tract and a 3' splice acceptor site; c) a spacer region that separates the 3' splice region from the target binding domain; d) a safety sequence comprising one or more complementary sequences that bind to one or both sides of the 3' splice site; and e) a nucleotide sequence to be trans-spliced to the target pre-mRNA; wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell. 17. A nucleic acid molecule comprising: a) one or more target binding domains wherein the target binding domain is a random nucleotide sequence that targets binding to a pre-mRNA expressed within the cell; b) a 5' splice site; c) a spacer region that separates the 5' splice site from the target blinding domain; d) a safety sequence comprising one or more complementary sequences that bind to one or both sides of the 5' splice site; and e) a nucleotide sequence to be trans-spliced to the target pre-mRNA; wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell. 18. The nucleic acid molecule of claim 16 or 17 wherein the nucleic acid molecule further comprises a 5' donor site. 19. The nucleic acid molecule of claim 16 or 17 wherein the binding of the nucleic acid molecule to the target pre-mRNA is mediated by complementarity, triple helix formation, or protein-nucleic acid interaction. 20. The nucleic acid molecule of claim 16 or 17 wherein the nucleotide to be trans-spliced to the target pre-mRNA comprises sequences encoding a translatable polypeptide tag. 21. The nucleic acid molecule of claim 16 or 17 wherein the nucleotide sequence to be trans-spliced to the target pre-mRNA comprises a nucleotide sequence tag. 22. The nucleic acid molecule of claim 18 wherein the binding of the nucleic acid molecule to the target pre-mRNA is mediated by complementarity, triple helix formation, or protein-nucleic acid interaction. 23. The nucleic acid molecule of claim 18 wherein the nucleotide sequence to be trans-spliced to the target pre-mRNA comprises sequences encoding a translatable polypeptide tag. 24. The nucleic acid molecule of claim 18 wherein the nucleotide sequence to be trans-spliced to the target pre-mRNA comprises a nucleotide sequence tag. 25. A eukaryotic expression vector wherein said vector expresses a nucleic acid molecule comprising: a) one or more target binding domains wherein the target binding domain is a random nucleotide sequence that targets binding to a pre-mRNA expressed within the cell; b) a 3' splice region comprising a branch point, a pyrimidine tract and a 3' splice acceptor site; c) a spacer region that separates the 3' splice region from the target binding domain; and d) a nucleotide sequence to be trans-spliced to the target pre-mRNA; wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell. 26. A eukaryotic expression vector wherein said vector expresses a nucleic acid molecule comprising: a) one or more target binding domains wherein the target binding domain is a random nucleotide sequence that targets binding to a pre-mRNA expressed within the cell; b) a 5' splice site; c) a spacer region that separates the 5' splice site from the target binding domain; and d) a nucleotide sequence to be trans-spliced to the target pre-mRNA; wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell. 27. The vector of claim 25 wherein the nucleic acid molecule further comprises a 5' donior site. 28. An expression library comprising recombinant expression vectors wherein said vectors expresses a nucleic acid molecule comprising: a) one or more target binding domains wherein the target binding domain is a random nucleotide sequence that targets binding to a pre-mRNA expressed within the cell; b) a 3' splice region comprising a branch point, a pyrimidine tract and a 3' splice acceptor site; c) a spacer region that separates the 3' splice region from the target binding domain; and (d) a nucleotide sequence to be trans-spliced to the target pre-mRNA; wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell. 29. An expression library comprising recombinant expression vectors wherein said wherein said vector expresses a nucleic acid molecule comprising: a) one or more target binding domains wherein the target binding domain is a random nucleotide sequence that targets binding to a pre-mRNA expressed within the cell; b) a 5' splice site; c) a spacer region that separates the 5' splice site from the target binding domain; and d) a nucleotide sequence to be trans-spliced to the target pre-mRNA; wherein said nucleic acid molecule is recognized by nuclear splicing components within the cell. 30. The expression library of claim 28 wherein the nucleic acid molecule further comprises a 5" donor site. 31. The expression library of claim 26 or 27 wherein the nucleotide sequence to be spliced to the target pre-mRNA comprises a nucelotide sequence tag. 32. The expression library of claim 26 or 27 wherein the nucleotide sequence to be spliced to the target pre-mRNA comprises a sequence encoding a translatable polypeptide tag. 33. A method for mapping exon-intron boundaries in pre-mRNA molecules comprising: (i) contacting a nucleic acid molecule containing a target binding domain wherein the target binding domain is a random nucleotide sequence that targets binding to a target pre-mRNA molecule, under conditions in which a portion of the nucleic acid molecule is trans-spliced to a portion of the target pre-mRNA to form a chimeric mRNA; (ii) amplifying the chimeric mRNA molecule; (iii) selectively purifying the amplified molecule; and iv) determining the nucleotide sequence of the amplified molecule thereby identifying the intron-exon boundaries. 34. A method for identifying proteins expressed in a cell comprising: (i) contacting a nucleic acid molecule containing a nucleotide sequence encoding a peptide tag or marker and a target binding domain wherein the target binding domain is a random nucleotide sequence with a pre-mRNA molecule under conditions in which a portion of the pre-trans-splicing molecule is trans-spliced to a portion of the target pre-mRNA to from a chimeric mRNA encoding a fusion polypeptide; (ii) affinity purifying the fusion polypeptide; and (iii) determining the peptide sequence of the fusion protein. 35. The method of claim 34 wherein the fusion polypeptide is a HIS polypeptide. 36. The method of claim 34 wherein the fusion polypeptide is a FLAG polypeptide. 37. The method of claim 34 wherein the fusion polypeptide is a glutathione-S-transferase polypeptide.

Details for Patent 6,083,702

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2015-12-15
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2015-12-15
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2015-12-15